In-111-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR

In-111-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR

Bibliografiset tiedot
Päätekijät:	Reilly, R, Kiarash, R, Cameron, R, Porlier, N, Sandhu, J, Hill, R, Vallis, K, Hendler, A, Gariepy, J
Aineistotyyppi:	Conference item
Julkaistu:	2000

Samankaltaisia teoksia

111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR.
Tekijä: Reilly, R, et al.
Julkaistu: (2000)

A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer.
Tekijä: Reilly, R, et al.
Julkaistu: (2000)

Comparative antiproliferative effects of (111)In-DTPA-hEGF, chemotherapeutic agents and gamma-radiation on EGFR-positive breast cancer cells.
Tekijä: Chen, P, et al.
Julkaistu: (2002)

Amplified delivery of indium-111 to EGFR-positive human breast cancer cells.
Tekijä: Wang, J, et al.
Julkaistu: (2001)

The anti-tumor effect of the auger electron-emitting radiopharmaceutical, In-111-hEGF against MDA-MB-468 human breast cancer xenografts is tumor-size dependent.
Tekijä: Chen, P, et al.
Julkaistu: (2001)

Accumulation of 111In-Labelled EGF-Au-PEG Nanoparticles in EGFR-Positive Tumours is Enhanced by Co-administration of Targeting Ligand
Tekijä: Song, L, et al.
Julkaistu: (2017)

Effect of the EGFR density of breast cancer cells on nuclear importation, in vitro cytotoxicity, and tumor and normal-tissue uptake of [111In]DTPA-hEGF.
Tekijä: Hu, M, et al.
Julkaistu: (2007)

An 111In-labelled bis-ruthenium(ii) dipyridophenazine theranostic complex: mismatch DNA binding and selective radiotoxicity towards MMR-deficient cancer cells
Tekijä: Gill, MR, et al.
Julkaistu: (2020)

Relationship between induction of phosphorylated H2AX and survival in breast cancer cells exposed to 111In-DTPA-hEGF.
Tekijä: Cai, Z, et al.
Julkaistu: (2008)

Computational analysis of the number, area and density of gamma-H2AX foci in breast cancer cells exposed to (111)In-DTPA-hEGF or gamma-rays using Image-J software.
Tekijä: Cai, Z, et al.
Julkaistu: (2009)

Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
Tekijä: Chen, P, et al.
Julkaistu: (2003)

SPECT imaging and biodistribution studies of 111In-EGF-Au-PEG nanoparticles in vivo
Tekijä: Song, L, et al.
Julkaistu: (2016)

111In-labelled polymeric nanoparticles incorporating a ruthenium-based radiosensitizer for EGFR-targeted combination therapy in oesophageal cancer cells
Tekijä: Gill, M, et al.
Julkaistu: (2018)

A phase I trial of In-111-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer
Tekijä: Vallis, K, et al.
Julkaistu: (2008)

A phase I clinical trial to evaluate the pharmacokinetics, toxicity and dosimetry of 111-indium-labeled human epidermal growth factor in patients with metastatic breast cancer
Tekijä: Vallis, K, et al.
Julkaistu: (2005)

Targeted Delivery of 111In Into the Nuclei of EGFR Overexpressing Cells via Modular Nanotransporters With Anti-EGFR Affibody
Tekijä: Tatiana S. Karyagina, et al.
Julkaistu: (2020-03-01)

Drug-encapsulating EGF-sensitive liposomes for EGF-overexpressing cancer therapies
Tekijä: Wong, Albert, S.M. Massachusetts Institute of Technology
Julkaistu: (2010)

(111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.
Tekijä: Costantini, D, et al.
Julkaistu: (2007)

Promising Gene Therapeutics for Salivary Gland Radiotoxicity
Tekijä: Renjith Parameswaran Nair, et al.
Julkaistu: (2016-11-01)

ErbB-2 blockade and prenyltransferase inhibition alter epidermal growth factor and epidermal growth factor receptor trafficking and enhance (111)In-DTPA-hEGF Auger electron radiation therapy.
Tekijä: Cornelissen, B, et al.
Julkaistu: (2011)

EGF-coated gold nanoparticles provide an efficient nano-scale delivery system for the molecular radiotherapy of EGFR-positive cancer.
Tekijä: Song, L, et al.
Julkaistu: (2016)

A phase I study of Tc-99m-h-R3 monoclonal antibody (DiaCIM (R)), a humanized monoclonal antibody (mAB) for imaging EGFR-positive malignancies.
Tekijä: Reilly, R, et al.
Julkaistu: (2002)

A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications.
Tekijä: Reilly, R, et al.
Julkaistu: (2004)

111In-labeled immunoconjugates (ICs) bispecific for the epidermal growth factor receptor (EGFR) and cyclin-dependent kinase inhibitor, p27Kip1.
Tekijä: Cornelissen, B, et al.
Julkaistu: (2009)

SMOC Binds to Pro-EGF, but Does Not Induce Erk Phosphorylation via the EGFR.
Tekijä: J Terrig Thomas, et al.
Julkaistu: (2016-01-01)

Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer.
Tekijä: Reilly, R, et al.
Julkaistu: (2006)

EGF Functionalized Polymer-Coated Gold Nanoparticles Promote EGF Photostability and EGFR Internalization for Photothermal Therapy.
Tekijä: Catarina Oliveira Silva, et al.
Julkaistu: (2016-01-01)

Indium-111 labelling of liposomal HEGF for radionuclide delivery via ultrasound-induced cavitation
Tekijä: Owen, J, et al.
Julkaistu: (2019)

Auger electron therapy using In-111-labelled F3 peptide
Tekijä: Cornelissen, B, et al.
Julkaistu: (2011)

Antisense imaging of epidermal growth factor (EGF) induced p21(WAF-1/CIP-1) mRNA in MDA-MB-468 human breast cancer xenografts.
Tekijä: Wang, J, et al.
Julkaistu: (2002)

RIZ2 at the crossroad of the EGF/EGFR signaling in colorectal cancer
Tekijä: Marzia Di Donato, et al.
Julkaistu: (2023-10-01)

Antitumor Activity of Auger Electron Emitter 111In Delivered by Modular Nanotransporter for Treatment of Bladder Cancer With EGFR Overexpression
Tekijä: Andrey A. Rosenkranz, et al.
Julkaistu: (2018-11-01)

Molecular Biomarkers for Predicting Cancer Patient Radiosensitivity and Radiotoxicity in Clinical Practice
Tekijä: Angeliki Gkikoudi, et al.
Julkaistu: (2023-11-01)

Effect of radiotoxic effect of uranium ore dust on the reproductive system of rats
Tekijä: Toklayeva Sevda, et al.
Julkaistu: (2019-01-01)

Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab.
Tekijä: Costantini, D, et al.
Julkaistu: (2010)

Preoperative Localization of a Gastrin-Secreting Tumour by Total Body Imaging with 111Indium-Labelled Pentatreotide
Tekijä: Humera Ali, et al.
Julkaistu: (1994-01-01)

Phase I trial to evaluate the tumor and normal tissue uptake, radiation dosimetry and safety of (111)In-DTPA-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer.
Tekijä: Vallis, K, et al.
Julkaistu: (2014)

Expression of EGF, EGFR, and proliferation in placentas from pregnancies complicated with preeclampsia
Tekijä: Indira Kosovic, et al.
Julkaistu: (2017-01-01)

Folliculin Interacts with Rab35 to Regulate EGF-Induced EGFR Degradation
Tekijä: Jianchao Zheng, et al.
Julkaistu: (2017-09-01)

HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant
Tekijä: Natthaporn Sueangoen, et al.
Julkaistu: (2020-03-01)